To the full analysis
Buyback calculator for Egetis Therapeutics
Egetis Therapeutics stock: dividend
EGTX.STEgetis Therapeutics does not currently pay a dividend. From fiscal 2023 to 2025, Egetis Therapeutics bought back its own shares for $150.41K.
Whether Egetis Therapeutics AB (publ) pays a dividend and what the company does with its cash instead: free cash flow, buybacks of its own shares and the share count over recent years.
Daily figure as of 13 Nov 2026
Free cash flow and buybacks
| Fiscal year | Free cash flow | Share buybacks | Shares outstanding |
|---|---|---|---|
| 2025 | −$26.93M | $0 | 368.19M |
| 2024 | −$22.85M | $150.41K | 306.54M |
| 2023 | −$27.92M | $0 | 256.75M |
| 2022 | −$17.4M | $0 | 194.24M |
| 2021 | −$13.06M | $0 | 179.91M |
Data status and sources
- Score
- Daily value of 13 Nov 2026, recalculated nightly
- Price
- Closing price of 12 Nov 2026
- Latest annual report
- Fiscal year 2025, period end 31 Dec 2025
- Currency
- Amounts in US dollars, converted at the ECB reference rate of 12 Nov 2026 ($1 = SEK 9.9729)
- Source
- Financial statements, ratios and prices from Financial Modeling Prep (FMP), based on the company's reports. MEQIRI calculates the score and fair value from them.
Mandatory disclosures for this rating
- ; time horizon around 12 months
- Rated Weak, published since 7 Nov 2026 (in the score history since 31 Mar 2012)
- Valuation signal Overvalued since 7 Nov 2026
- End-of-day prices, metrics cached for up to 24 hours
- Score and fair value are estimates from a disclosed model. They are not facts and not a price target.
- Produced by SSM Ventures UG (haftungsbeschränkt), responsible person Sven Brostmeyer, Managing Director, automatically according to the disclosed model.
- Not investment advice. Losses up to and including a total loss are possible. Personal circumstances are not considered.